Table 2.

Multivariable analysis of predictors of chemotherapy-induced peripheral neuropathy prevalence ¹ in the Detroit Research on Cancer Survivors (ROCS) Cohort

	aOR*	Lower CI	Upper CI
Demographics
Age at Diagnosis (per age group)	0.66	0.53	0.83
Marital Status
Married or equivalent	1.24	0.86	1.79
Widowed	1.34	0.80	2.26
Divorced or separated	2.13	1.42	3.21
Never married	ref
Educational attainment (per category)	1.10	0.97	1.26
Cancer characteristics
Cancer Site
Breast	3.88	2.02	7.46
Colorectal	5.37	2.69	10.73
Lung	1.15	0.58	2.28
Prostate	ref
SEER summary stage
Local	0.79	0.50	1.25
Regional	1.01	0.67	1.53
Distant	ref
Trend	1.15	0.92	1.45
Medical history
BMI at enrollment (per category)	1.14	0.94	1.38
Comorbidity count
None	ref
1	1.46	0.81	2.62
2	1.51	0.84	2.73
3	1.45	0.78	2.73
4 or more	1.76	0.95	3.25
Trend	1.10	0.97	1.24
Diabetes mellitus
Yes	0.88	0.62	1.24
No	ref
Thyroid problem
Yes	1.00	0.63	1.59
No	ref
Arthritis
Yes	1.05	0.78	1.42
No	ref
Smoker (≥ 100 cigs lifetime)
Yes	1.20	0.87	1.65
No	ref
Alcohol use (in the past 4 weeks)
Yes	1.10	0.81	1.49
No	ref

^*Multivariable adjustment for age at diagnosis, marital status, education, cancer site, SEER summary stage, body mass index at enrollment, and smoking

CIPN prevalence was defined by the presence of self-reported PN symptoms (pain, numbness, or tingling in the hands or feet) at any time since starting chemotherapy or worsening of any prior PN symptoms after chemotherapy administration

Bold values denote statistical signicance at p<0.05